7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Vestibulocochlear Nerve Diseases D000160 1 associated lipids
Acromegaly D000172 6 associated lipids
Actinobacillus Infections D000189 4 associated lipids
Actinomycosis D000196 2 associated lipids
Addison Disease D000224 3 associated lipids
Adenocarcinoma D000230 166 associated lipids
Adrenal Hyperplasia, Congenital D000312 2 associated lipids
Albuminuria D000419 18 associated lipids
Alzheimer Disease D000544 76 associated lipids
Angina, Unstable D000789 14 associated lipids
Angioid Streaks D000793 1 associated lipids
Ankylosis D000844 1 associated lipids
Aortic Diseases D001018 11 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Arthritis, Rheumatoid D001172 3 associated lipids
Arthropathy, Neurogenic D001177 1 associated lipids
Atrial Fibrillation D001281 16 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Biliary Atresia D001656 4 associated lipids
Body Weight D001835 333 associated lipids
Bone Diseases, Developmental D001848 2 associated lipids
Bone Diseases, Endocrine D001849 1 associated lipids
Bone Diseases, Metabolic D001851 9 associated lipids
Bone Neoplasms D001859 5 associated lipids
Bone Resorption D001862 7 associated lipids
Cachexia D002100 21 associated lipids
Calcinosis D002114 5 associated lipids
Carcinoid Heart Disease D002275 1 associated lipids
Carcinoma D002277 18 associated lipids
Carcinoma, Non-Small-Cell Lung D002289 72 associated lipids
Carcinoma, Papillary D002291 3 associated lipids
Carcinosarcoma D002296 7 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Celiac Disease D002446 16 associated lipids
Brain Ischemia D002545 89 associated lipids
Cherubism D002636 1 associated lipids
Chondroblastoma D002804 1 associated lipids
Chondrocalcinosis D002805 1 associated lipids
Chronic Disease D002908 7 associated lipids
Cleidocranial Dysplasia D002973 1 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Coronary Disease D003327 70 associated lipids
Crohn Disease D003424 12 associated lipids
Cryptosporidiosis D003457 3 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Dengue D003715 2 associated lipids
Dental Occlusion, Traumatic D003769 1 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Theoleyre S et al. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. 2004 Cytokine Growth Factor Rev. pmid:15561602
Mori T et al. RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family. 2004 Nucleic Acids Res. pmid:15562003
Ogasawara T et al. In situ expression of RANKL, RANK, osteoprotegerin and cytokines in osteoclasts of rat periodontal tissue. 2004 J. Periodont. Res. pmid:14687227
Blair HC and Athanasou NA Recent advances in osteoclast biology and pathological bone resorption. 2004 Histol. Histopathol. pmid:14702187
Kumamoto H and Ooya K Expression of parathyroid hormone-related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG) in ameloblastomas. 2004 J. Oral Pathol. Med. pmid:14675140
Suda K et al. Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation. 2004 J. Immunol. pmid:14764723
Brubaker KD et al. Bone morphogenetic protein signaling in prostate cancer cell lines. 2004 J. Cell. Biochem. pmid:14689587
Onyia JE et al. Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption. 2004 J. Pharmacol. Exp. Ther. pmid:14718597
Smith MD Comment on review on T cells in bone biology. 2004 Rheumatology (Oxford) pmid:15448222
Boabaid F et al. Leucine-rich amelogenin peptide: a candidate signaling molecule during cementogenesis. 2004 J. Periodontol. pmid:15455742
Jørgensen HL et al. Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios. 2004 J. Bone Miner. Metab. pmid:14999524
Kobayashi-Sakamoto M et al. NF-kappaB-dependent induction of osteoprotegerin by Porphyromonas gingivalis in endothelial cells. 2004 Biochem. Biophys. Res. Commun. pmid:15013432
MacQuarrie RA et al. Wear-particle-induced osteoclast osteolysis: the role of particulates and mechanical strain. 2004 J. Biomed. Mater. Res. Part B Appl. Biomater. pmid:15015218
Ishii T et al. Osteopontin as a positive regulator in the osteoclastogenesis of arthritis. 2004 Biochem. Biophys. Res. Commun. pmid:15033472
Suda T and Miyaura C [Recent advance in basic research for osteoporosis]. 2004 Nippon Rinsho pmid:15035090
Matsumoto T [Recent advances in the regulation of bone remodeling]. 2004 Nippon Rinsho pmid:15035093
Okumura S et al. [Regulatory mechanism of osteoclast differentiation and function]. 2004 Nippon Rinsho pmid:15035103
Udagawa N et al. [Possible role of RANKL in bone resorption]. 2004 Nippon Rinsho pmid:15035104
Inoue D [OPG(osteoprotegerin)/OCIF(osteoclastogenesis inhibitory factor)]. 2004 Nippon Rinsho pmid:15035105
Suzuki Y [Stimulator of bone resorption interleukin-1, interleukin-6 and gp-130 cytokine family]. 2004 Nippon Rinsho pmid:15035106
Miyaura C [LPS]. 2004 Nippon Rinsho pmid:15035108
Tanaka Y [Adhesion molecules in the context with bone remodeling and osteoporosis]. 2004 Nippon Rinsho pmid:15035110
Tomoyasu A and Higashio K [Osteoclastogenesis inhibitory factor/osteoprotegerin(OCIF/OPG)]. 2004 Nippon Rinsho pmid:15035190
Sohen S [Glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis and collagen diseases]. 2004 Nippon Rinsho pmid:15035207
Tanaka Y [Secondary osteoporosis due to systemic autoimmune diseases and rheumatic diseases]. 2004 Nippon Rinsho pmid:15035208
Bergh JJ et al. Osteoprotegerin expression and secretion are regulated by calcium influx through the L-type voltage-sensitive calcium channel. 2004 Endocrinology pmid:14525906
Naumann U et al. Expression and functional activity of osteoprotegerin in human malignant gliomas. 2004 Acta Neuropathol. pmid:14504888
Saidenberg-Kermanac'h N et al. Interleukin-4 cellular gene therapy and osteoprotegerin decrease inflammation-associated bone resorption in collagen-induced arthritis. 2004 J. Clin. Immunol. pmid:15163893
Wise GE et al. Regulation of secretion of osteoprotegerin in rat dental follicle cells. 2004 Eur. J. Oral Sci. pmid:15458504
Dai SM et al. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha. 2004 Ann. Rheum. Dis. pmid:15479886
Wang JC et al. Osteosclerosis in idiopathic myelofibrosis is related to the overproduction of osteoprotegerin (OPG). 2004 Exp. Hematol. pmid:15504545
Chen Q et al. Testosterone increases osteoprotegerin mRNA expression in mouse osteoblast cells. 2004 Horm. Metab. Res. pmid:15523591
Saidenberg-Kermanac'h N et al. TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. 2004 Bone pmid:15542046
Boabaid F et al. The role of parathyroid hormone-related protein in the regulation of osteoclastogenesis by cementoblasts. 2004 J. Periodontol. pmid:15515341
Fan X et al. Nitric oxide regulates receptor activator of nuclear factor-kappaB ligand and osteoprotegerin expression in bone marrow stromal cells. 2004 Endocrinology pmid:14563699
Price PA et al. Serum levels of the fetuin-mineral complex correlate with artery calcification in the rat. 2004 J. Biol. Chem. pmid:14578360
Daroszewska A et al. Susceptibility to Paget's disease of bone is influenced by a common polymorphic variant of osteoprotegerin. 2004 J. Bone Miner. Res. pmid:15312251
Liu JM et al. [The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75]. 2004 Zhonghua Nei Ke Za Zhi pmid:15312444
Jacobson A et al. Vitamin A differentially regulates RANKL and OPG expression in human osteoblasts. 2004 Biochem. Biophys. Res. Commun. pmid:15313187
Ishida M and Amano S Osteocalcin fragment in bone matrix enhances osteoclast maturation at a late stage of osteoclast differentiation. 2004 J. Bone Miner. Metab. pmid:15316862
Sato T et al. Interleukin-11 as an osteoprotegerin-inducing factor in culture medium of blastic cells from a patient with acute megakaryocytic leukemia complicated with osteosclerosis. 2004 Am. J. Hematol. pmid:15307108
Giuliani N et al. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). 2004 Exp. Hematol. pmid:15308315
Colucci S et al. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. 2004 Blood pmid:15308561
Miyazaki T et al. Changes in receptor activator of nuclear factor-kappaB, and its ligand, osteoprotegerin, bone-type alkaline phosphatase, and tartrate-resistant acid phosphatase in ovariectomized rats. 2004 J. Cell. Biochem. pmid:15372622
Jeffcoate W Vascular calcification and osteolysis in diabetic neuropathy-is RANK-L the missing link? 2004 Diabetologia pmid:15322748
Liu Z et al. Production of recombinant human osteoprotegrin from Trichoplusia ni cells and Bombyx mori larvae. 2004 Protein Pept. Lett. pmid:15327363
Politou M et al. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). 2004 Br. J. Haematol. pmid:15327520
Erdogan B et al. Intima-media thickness of the carotid arteries is related to serum osteoprotegerin levels in healthy postmenopausal women. 2004 Neurol. Res. pmid:15327755
Hofbauer LC and Schoppet M Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. 2004 JAMA pmid:15280347
Kanatani M et al. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction. 2004 J. Cell. Physiol. pmid:15281085
Xiao XH et al. [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro]. 2004 Zhonghua Yi Xue Za Zhi pmid:15730627
Matsuo K and Ray N Osteoclasts, mononuclear phagocytes, and c-Fos: new insight into osteoimmunology. 2004 Keio J Med pmid:15247511
Tiranathanagul S et al. Actinobacillus actinomycetemcomitans lipopolysaccharide activates matrix metalloproteinase-2 and increases receptor activator of nuclear factor-kappaB ligand expression in human periodontal ligament cells. 2004 J. Periodontol. pmid:15732867
Buxton EC et al. Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). 2004 J. Clin. Endocrinol. Metab. pmid:15240611
Kochanowska I et al. Influence of osteoprotegerin (OPG) on resorption of heterotopically induced ossicle. 2004 Cell Tissue Bank pmid:15241009
Corso A et al. Osteoprotegerin serum levels in multiple myeloma and MGUS patients compared with age- and sex-matched healthy controls. 2004 Leukemia pmid:15241438
Harada M et al. Concentration of osteoprotegerin (OPG) in peritoneal fluid is increased in women with endometriosis. 2004 Hum. Reprod. pmid:15242994
Kang HS et al. Receptor activator of nuclear factor-kappaB is induced by a rottlerin-sensitive and p38 MAP kinase-dependent pathway during monocyte differentiation. 2004 Mol. Cells pmid:15232218
Kazama JJ Osteoprotegerin and bone mineral metabolism in renal failure. 2004 Curr. Opin. Nephrol. Hypertens. pmid:15199291
Walsh NC and Gravallese EM Bone loss in inflammatory arthritis: mechanisms and treatment strategies. 2004 Curr Opin Rheumatol pmid:15201606
Terpos E et al. Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. 2004 Leukemia pmid:15215875
Brändström H et al. A single nucleotide polymorphism in the promoter region of the osteoprotegerin gene is related to intima-media thickness of the carotid artery in hypertensive patients. The Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA). 2004 Blood Press. pmid:15223723
Wilson SE et al. RANK, RANKL, OPG, and M-CSF expression in stromal cells during corneal wound healing. 2004 Invest. Ophthalmol. Vis. Sci. pmid:15223796
Pioletti DP and Kottelat A The influence of wear particles in the expression of osteoclastogenesis factors by osteoblasts. 2004 Biomaterials pmid:15172492
Livshits G et al. Genetic influences on the circulating cytokines involved in osteoclastogenesis. 2004 J. Med. Genet. pmid:15173242
De Wilde A et al. A low dose of daidzein acts as an ERbeta-selective agonist in trabecular osteoblasts of young female piglets. 2004 J. Cell. Physiol. pmid:15174095
Taranta A et al. Imbalance of osteoclastogenesis-regulating factors in patients with celiac disease. 2004 J. Bone Miner. Res. pmid:15176994
Demer LL and Abedin M Skeleton key to vascular disease. 2004 J. Am. Coll. Cardiol. pmid:15542279
Vidal K et al. Osteoprotegerin production by human intestinal epithelial cells: a potential regulator of mucosal immune responses. 2004 Am. J. Physiol. Gastrointest. Liver Physiol. pmid:15521102
Lee CK et al. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. 2004 Arthritis Rheum. pmid:15593184
Grzegorzewska AE and MÅ‚ot M Ratio of cyclase activating and cyclase inactive parathormone (CAP/CIP) in dialysis patients: correlations with other markers of bone disease. 2004 Rocz. Akad. Med. Bialymst. pmid:15631341
Grzegorzewska AE and MÅ‚ot M Serum osteoprotegerin level is lower in peritoneal dialysis patients than in hemodialysis ones. 2004 Rocz. Akad. Med. Bialymst. pmid:15631342
Naumnik W et al. Serum levels of osteoprotegerin (OPG) and pro gastrin releasing peptide (ProGRP) during chemotherapy of lung cancer. 2004 Rocz. Akad. Med. Bialymst. pmid:15638385
Franchimont N et al. Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. 2004 Clin. Exp. Immunol. pmid:15544627
Masi L et al. Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury? 2004 J. Rheumatol. pmid:15124262
Eaton CL et al. Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. 2004 Prostate pmid:15042606
Nitta K et al. Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. 2004 Nephrol. Dial. Transplant. pmid:15128884
O' Gradaigh D et al. Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts. 2004 Ann. Rheum. Dis. pmid:15020327
Milstead JR et al. Spaceflight and hindlimb suspension disuse models in mice. 2004 Biomed Sci Instrum pmid:15133943
Collantes Estévez E and González Domínguez J [Bone Paget's disease in the young adult]. 2004 Rev Clin Esp pmid:15456600
Karst M et al. Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation. 2004 J. Cell. Physiol. pmid:15137062
Sato N et al. MyD88 but not TRIF is essential for osteoclastogenesis induced by lipopolysaccharide, diacyl lipopeptide, and IL-1alpha. 2004 J. Exp. Med. pmid:15353553
Emanuele E et al. Plasma osteoprotegerin as a biochemical marker for vascular dementia and Alzheimer's disease. 2004 Int. J. Mol. Med. pmid:15138623
Mizutani Y et al. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma. 2004 Cancer pmid:15386310
Kyrtsonis MC et al. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. 2004 Eur. J. Haematol. pmid:15089762
Miao D et al. Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice. 2004 Endocrinology pmid:15090463
Haynes DR et al. Regulation of osteoclast activity in peri-implant tissues. 2004 Biomaterials pmid:15109848
Ito S and Hata T Crystal structure of RANK ligand involved in bone metabolism. 2004 Vitam. Horm. pmid:15110169
Hao C et al. Modulation of TRAIL signaling complex. 2004 Vitam. Horm. pmid:15110173
Kiechl S et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. 2004 Circulation pmid:15117849
Pritzker LB et al. The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. 2004 Mol. Biol. Cell pmid:15064358
Salmon P Loss of chaotic trabecular structure in OPG-deficient juvenile Paget's disease patients indicates a chaogenic role for OPG in nonlinear pattern formation of trabecular bone. 2004 J. Bone Miner. Res. pmid:15068491
Morabito N et al. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. 2004 J. Bone Miner. Res. pmid:15068494
Jono S [Risk factors of atherosclerosis in end-stage renal disease patients]. 2004 Clin Calcium pmid:15576949
Shimizu M and Tamura T [Regulation of bone mineralization by parathyroid hormone]. 2004 Clin Calcium pmid:15577058
Ogata H et al. [Prophylaxis and treatment of adynamic bone]. 2004 Clin Calcium pmid:15577107
Altun A et al. Decreased serum osteoprotegerin levels in patients with cardiac syndrome X. 2004 J. Endocrinol. Invest. pmid:15648548
Kanzaki H et al. Local OPG gene transfer to periodontal tissue inhibits orthodontic tooth movement. 2004 J. Dent. Res. pmid:15557398
Cheng X et al. Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo. 2004 J. Biol. Chem. pmid:14679212
Zhang X et al. Synovial fibroblasts infected with Salmonella enterica serovar Typhimurium mediate osteoclast differentiation and activation. 2004 Infect. Immun. pmid:15557643

Table of Content